RYR2 and catecholaminergic polymorphic ventricular tachycardia: A total of 200 participants (median age 33.5 [22.0–50.0] years) used medication for CPVT, of whom 122 (61.0%) were female and 109 (54.5%) reported to be a carrier of a RYR2 gene variant.